Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">AveXis announces update to its AVXS-101 study in SMA Type 1 in the EU; expects to initiate a separate pivotal clinical trial of AVXS-101 in SMA Type 1 in the US in 1H17 (58.98)<p>Co announced that the planned pivotal study of AVXS-101 in spinal muscular atrophy Type 1 in the EU <strong>will reflect a single-arm design</strong>, using natural history of the disease as a comparator, and will enroll ~30 patients.</p><ul><li>This update is <strong>based on the receipt of the Scientific Advice response</strong> from the Scientific Advice Working Party within the CHMP of the EMA.<ul><li>The CHMP additionally recommended co discuss the potential for Conditional Marketing Authorization in a future meeting with EMA.</li></ul></li><li>More specific clinical trial details will be made available at the time the study is initiated, which is expected in 2H17.</li><li>Co expects to initiate a separate pivotal clinical trial of AVXS-101 in SMA Type 1 in the United States in 1H17.</li></ul></td> </tr></table>"